中国药物与临床
中國藥物與臨床
중국약물여림상
Chinese Remedies & Clinics
2015年
11期
1553-1556
,共4页
陆琳松%孙俊刚%钟惠琴%孙治国%周文正%殷剑%肖伟%王浩%袁宏
陸琳鬆%孫俊剛%鐘惠琴%孫治國%週文正%慇劍%肖偉%王浩%袁宏
륙림송%손준강%종혜금%손치국%주문정%은검%초위%왕호%원굉
骨质疏松%唑来膦酸%骨密度%老年男性%哈萨克族
骨質疏鬆%唑來膦痠%骨密度%老年男性%哈薩剋族
골질소송%서래련산%골밀도%노년남성%합살극족
Osteoporosis%Zoledronic acid%Bone density%Elderly male%Kazak
目的 探讨注射用唑来膦酸5 mg对新疆哈萨克族老年男性骨质疏松患者的临床疗效.方法 选取2011年6月至2013年11月住院期间哈萨克族老年男性骨质疏松患者62例,所有患者均初次诊断为骨质疏松症,未曾行任何抗骨质疏松治疗,同时排除其他骨代谢性疾病或药物影响,随机分为治疗组(32例),给予唑来膦酸5 mg,静脉滴注30 min,同时口服碳酸钙D3(钙尔奇)600 mg/d及1α-羟基维生素D3 0.25 μg/d;对照组(30例),给予口服碳酸钙D3 600 mg/d及1α-羟基维生素D3 0.25 μg/d,治疗时间1年,采用双能X线骨密度仪(DEXA)测定2组治疗前后的腰椎1-4、股骨颈、Ward三角区骨密度值.结果 排除治疗组中2例患者脱失外,治疗组骨密度增幅程度均显著高于对照组(P<0.05).6例患者在注射唑来膦酸后出现发热、头痛及流感样症状,给予非甾体抗炎药(NSAIDs)对症治疗后6例患者均在3 d内缓解,未见其他不良反应.结论 唑来膦酸注射液5 mg可明显提高新疆哈萨克族老年男性骨质疏松患者的骨密度,抑制骨量丢失,降低骨折风险,提高患者依从性,不良反应可耐受,是治疗新疆哈萨克族老年男性骨质疏松患者的高效药物.
目的 探討註射用唑來膦痠5 mg對新疆哈薩剋族老年男性骨質疏鬆患者的臨床療效.方法 選取2011年6月至2013年11月住院期間哈薩剋族老年男性骨質疏鬆患者62例,所有患者均初次診斷為骨質疏鬆癥,未曾行任何抗骨質疏鬆治療,同時排除其他骨代謝性疾病或藥物影響,隨機分為治療組(32例),給予唑來膦痠5 mg,靜脈滴註30 min,同時口服碳痠鈣D3(鈣爾奇)600 mg/d及1α-羥基維生素D3 0.25 μg/d;對照組(30例),給予口服碳痠鈣D3 600 mg/d及1α-羥基維生素D3 0.25 μg/d,治療時間1年,採用雙能X線骨密度儀(DEXA)測定2組治療前後的腰椎1-4、股骨頸、Ward三角區骨密度值.結果 排除治療組中2例患者脫失外,治療組骨密度增幅程度均顯著高于對照組(P<0.05).6例患者在註射唑來膦痠後齣現髮熱、頭痛及流感樣癥狀,給予非甾體抗炎藥(NSAIDs)對癥治療後6例患者均在3 d內緩解,未見其他不良反應.結論 唑來膦痠註射液5 mg可明顯提高新疆哈薩剋族老年男性骨質疏鬆患者的骨密度,抑製骨量丟失,降低骨摺風險,提高患者依從性,不良反應可耐受,是治療新疆哈薩剋族老年男性骨質疏鬆患者的高效藥物.
목적 탐토주사용서래련산5 mg대신강합살극족노년남성골질소송환자적림상료효.방법 선취2011년6월지2013년11월주원기간합살극족노년남성골질소송환자62례,소유환자균초차진단위골질소송증,미증행임하항골질소송치료,동시배제기타골대사성질병혹약물영향,수궤분위치료조(32례),급여서래련산5 mg,정맥적주30 min,동시구복탄산개D3(개이기)600 mg/d급1α-간기유생소D3 0.25 μg/d;대조조(30례),급여구복탄산개D3 600 mg/d급1α-간기유생소D3 0.25 μg/d,치료시간1년,채용쌍능X선골밀도의(DEXA)측정2조치료전후적요추1-4、고골경、Ward삼각구골밀도치.결과 배제치료조중2례환자탈실외,치료조골밀도증폭정도균현저고우대조조(P<0.05).6례환자재주사서래련산후출현발열、두통급류감양증상,급여비치체항염약(NSAIDs)대증치료후6례환자균재3 d내완해,미견기타불량반응.결론 서래련산주사액5 mg가명현제고신강합살극족노년남성골질소송환자적골밀도,억제골량주실,강저골절풍험,제고환자의종성,불량반응가내수,시치료신강합살극족노년남성골질소송환자적고효약물.
Objective To investigate the clinical effect of 5 mg zoledronic acid for injection on osteoporosis in Xinjiang Kazak elderly male patients. Methods Sixty-two Kazak elderly male patients with osteoporosis hospitalized between June 2011 and November 2013 were included in the study. All patients were first diagnosed with osteoporo-sis, never received any anti-osteoporosis treatment, while excluding other bone metabolic diseases or the influence of drugs. All patients were randomly divided into the treatment group (n=32) and the control group (n=30). The treatment group was given 5 mg zoledronic acid, 30 min intravenous infusion, and 600 mg/d oral caltrate and 0.25 μg/d alpha D3, and the control group was given 600 mg/d oral caltrate and 0.25 μg/d alpha D3 for one-year treatment. The dual-energy X-ray absorptiometry (DEXA) was used to measure the bone mineral density (BMD) of lumbar spine 1-4, femoral neck, and Ward′s triangle region before and after the treatment. Results Excluding 2 patients dropped out in the treatment group, the increasing degree of BMD in the treatment group was significantly higher than that in the control group (P<0.05). Fever, headache and flu-like symptoms were found in six patients after the injection of Zole-dronic Acid. All 6 patients were relieved in 3 days after given symptomatic treatment of NSAIDs, without other ad-verse reactions. Conclusion Five mg zoledronic acid injection can significantly improve the BDM in Xinjiang Kazak elderly male patients with osteoporosis, inhibit bone loss, reduce fracture risk and improve patient compliance and ad-verse reaction tolerance, which is the highly-effective drug for the treatment of osteoporosis in Xinjiang Kazak elderly male patients.
